by Kazeem Olalekan MRPharmS The Medicines and Healthcare products Regulatory Agency has just issued a Class 4 Drug Safety Alert for Wockhardt UK Ltd – Amoxicillin Sodium 1g, 250mg and 500mg Powder for Solution for Injection. Alert details Drug alert number EL (14)A/09 in connection with the
Read more →
by Kazeem Olalekan A BNF and BNFc app convert like myself knows to press the ‘Update Now’ button whenever I am prompted to do so. It is the best way to be up-to-date in clinical decision making. What I thought I would do today is highlight some
Read more →
by Kazeem Olalekan Attention has just been drawn to the Drug Safety Update on Febuxostat (Adenuric) via the PJOnline website. In summary, there have been rare but serious reports of hypersensitivity reactions, including Stevens-Johnson syndrome and acute anaphylactic shock, with febuxostat (Adenuric). Febuxostat must be stopped immediately
Read more →
by Kazeem Olalekan MRPharmS In August 2009 we reported a potential interaction between Proton pump inhibitors (PPI) and Clopidogrel. Subsequent to that report, Lancet concluded that PPI does not interfere with the clinical benefits of clopidogrel. The case frustrated me because in one week I was asking
Read more →
Dronedarone (Multaq▼) is an antiarrhythmic agent indicated in adult, clinically stable patients with history of, or current, non-permanent atrial fibrillation (AF) to prevent recurrence of AF or to lower ventricular rate. Dronedarone is available as a 400 mg film-coated tablet and the recommended dose is 400 mg
Read more →
